Cargando…
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
PURPOSE: This phase 1 study assessed the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of linifanib in Japanese patients with advanced solid tumors. METHODS: Patients were assigned to one of four sequential cohorts (0.05, 0.10, 0.20, or 0.25 mg/kg) of oral, once-daily li...
Autores principales: | Asahina, Hajime, Tamura, Yosuke, Nokihara, Hiroshi, Yamamoto, Noboru, Seki, Yoshitaka, Shibata, Takashi, Goto, Yasushi, Tanioka, Maki, Yamada, Yasuhide, Coates, Andrew, Chiu, Yi-Lin, Li, Xiaohui, Pradhan, Rajendra, Ansell, Peter J., McKeegan, Evelyn M., McKee, Mark D., Carlson, Dawn M., Tamura, Tomohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362725/ https://www.ncbi.nlm.nih.gov/pubmed/22382879 http://dx.doi.org/10.1007/s00280-012-1846-6 |
Ejemplares similares
-
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
por: Seki, Yoshitaka, et al.
Publicado: (2011) -
Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS
por: Iqbal, Muzaffar, et al.
Publicado: (2014) -
Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer
por: Chen, Jing, et al.
Publicado: (2016) -
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2016) -
Linifanib
Publicado: (2012)